UK's Abingdon Health H1 revenue rises 37%, loss narrows

Abingdon Health

17/03/2026 07:16

Overview

UK rapid diagnostics developer's H1 revenue rose 37% yr/yr, total revenue up 45% with grants

Adjusted EBITDA loss narrowed as revenue growth offset higher investment in operations

Company expects H2 to be profitable and cash flow positive, maintains FY26 revenue guidance

Outlook

Abingdon Health maintains FY26 revenue guidance at £12.6 mln, in line with market expectations

Company expects H2 FY26 to be adjusted EBITDA and operating cash flow positive

Outlook for FY27 remains positive with major CDMO contracts expected to continue and support revenue growth

Result Drivers

CDMO AND REGULATORY SERVICES GROWTH - Revenue growth was driven by expansion in contract development, manufacturing and regulatory services, supported by major contract wins and an integrated service offering

US EXPANSION - Additional investment in US operations and new contract wins in the US contributed to revenue growth

CONTRACT AND CUSTOMER MIX - Gross margin percentage declined by 5 percentage points due to growth in regulatory services and customer/contract mix

Company press release: ID:nRSQ8536Wa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 4.24 mln
H1 Net Income
-GBP 2.35 mln
H1 Adjusted EBITDA
-GBP 1.70 mln
H1 EBIT
-GBP 2.28 mln
H1 Gross Profit
GBP 1.41 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Abingdon Health PLC is GBp61.00, about 639.4% above its March 16 closing price of GBp8.25

The stock recently traded at 44 times the next 12-month earnings vs. a P/E of 21 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)